Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report for the non-interventional imposed PASS final report for the medicinal product(s) containing the active substance dexketoprofen and tramadol (DKP-TRAM) and concerned by the PASS final report, the scientific conclusions are as follows.

Despite study limitations (as detailed in different sections of the PRAC rapporteur's team assessment report), which preclude to obtain robust conclusions, PRAC agreed that no new relevant concerns have emerged in relation to the safety profile or the pattern of use of DKP-TRAM.

PRAC confirmed that the obligation of performing the PASS is considered fulfilled. Thus, DKP-TRAM should be removed from the list of medicinal products subjected to additional monitoring.

DKP-TRAM product information already mentions that undesirable effects may be minimized by using the lowest number of doses for the shortest duration necessary to control symptoms. In addition, a warning about elderly patients and patients with several comorbidities (such as hepatic, renal or cardiovascular diseases among others) is already included. Therefore, no PI updates are warranted.

Furthermore, the risk management plan (RMP) should be updated at the next regulatory opportunity, in order to remove the completed study from all relevant sections of the document.

Ultimately, the benefit-risk balance of the concerned medicinal product(s) remains unchanged.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for the results of the study for the medicinal product(s) containing the active substance dexketoprofen and tramadol and concerned by the PASS final report, the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) mentioned above is unchanged subject to the proposed changes to the conditions of the marketing authorisation.

The CMDh reaches the position that the marketing authorisation(s) of the products concerned by this PASS final report should be varied.

Annex II

Conditions to the Marketing Authorisation(s)

Changes to be made to the conditions of the marketing authorisation(s) of medicinal product(s) containing the active substance dexketoprofen and tramadol concerned by the non-interventional imposed PASS final report

The marketing authorisation holder(s) shall remove the following condition(s) (new text **<u>underlined and in bold</u>,** deleted text ~~strike through~~)

- ~~The condition to submit the results of an imposed non-interventional PASS is fulfilled. The inclusion of dexketoprofen and tramadol-containing medicinal products in the List of medicinal products under additional monitoring is no more warranted.~~

Annex III

Timetable for the implementation of this position

Timetable for the implementation of the position

Adoption of CMDh position:	April 2022 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	6 June 2022
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	5 August 2022